Broker-Dealer AgreementBroker-Dealer Agreement • January 19th, 2023 • Algernon Neuroscience Inc. • Pharmaceutical preparations
This agreement (together with exhibits and schedules, the “Agreement”) is entered into by and between Algernon Neuroscience Inc (“Client”), a British Columbia Corporation, and Dalmore Group, LLC., a New York Limited Liability Company (“Dalmore”). Client and Dalmore agree to be bound by the terms of this Agreement, effective as of December 9, 2022 (the “Effective Date”):
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIALAlgernon Neuroscience Inc. • December 30th, 2022
Client is interested in conducting a study pursuant to the Protocol (as defined below); CHDR has the facilities and know-how to carry out such study;
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL MASTER SERVICES AGREEMENT This MASTER SERVICES AGREEMENT (the "Agreement") is...Master Services Agreement • December 30th, 2022 • Algernon Neuroscience Inc.
Dalton Chemical Laboratories, Inc. o/a Dalton Pharma Services, a corporation incorporated under the laws of the Province of Ontario, Canada whose principal operations are located at: 349 Wildcat Road, Toronto, ON, M3J 2S3, Canada together with its subsidiaries and affiliates (as defined below), (hereinafter referred to as "CONTRACTOR")
Broker-Dealer AgreementBroker-Dealer Agreement • December 30th, 2022 • Algernon Neuroscience Inc.
This agreement (together with exhibits and schedules, the "Agreement") is entered into by and between Algernon Pharmaceuticals, Inc ("Client"), a British Columbia Corporation, and Dalmore Group, LLC., a New York Limited Liability Company ("Dalmore"). Client and Dalmore agree to be bound by the terms of this Agreement, effective as of December 1, 2022 (the "Effective Date"):
MANAGEMENT SERVICES AGREEMENTManagement Services Agreement • December 30th, 2022 • Algernon Neuroscience Inc. • British Columbia
ALGERNON NEUROSCIENCE INC., a company incorporated pursuant to the laws of the Province of British Columbia, with an office at 1500 Royal Centre, Box 11117, 1055 West Georgia St., Vancouver
ASSET TRANSFER AND TRADEMARK LICENSE AGREEMENTAsset Transfer and Trademark License Agreement • December 30th, 2022 • Algernon Neuroscience Inc. • British Columbia
NOW THEREFORE, in consideration of the foregoing and the representations, warranties, covenants, conditions, agreements and promises contained in this Agreement and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the Vendor and the Purchaser (collectively, the "Parties" and "Party" means either of them) agree as follows:
